Breaking News

VintaBio Opens Custom-built Manufacturing Facility in Philadelphia for CGTs

Raises $64 million in funding and appoints David Radspinner CEO.

VintaBio, a life sciences company with expertise in viral vectors and cell and gene therapy development, has opened a custom-built manufacturing facility in Philadelphia. The company has also raised $64 million in funding and appointed David Radspinner CEO. VintaBio’s $64 million in funding, led by Decheng Capital, helped support the development of its 22,500-sq.-ft. Philadelphia facility, designed specifically to streamline cell and gene therapy development and manufacturing. Radspi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters